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Proprotein convertases are a family of kexin-like serine proteases that process proteins at single and multiple basic
residues. Among the predicted and identified PC substrates, an increasing number of proteins having functions in
cancer progression indicate that PCs may be potential targets for antineoplastic drugs. In support of this notion,
we identified PACE4 as a vital PC involved in prostate cancer proliferation and progression, contrasting with the
other co-expressed PCs. The aim of the present study was to test the importance of PCs in ovarian cancer cell
proliferation and tumor progression. Based on tissue-expression profiles, furin, PACE4, PC5/6 and PC7 all
displayed increased expression in primary tumor, ascites cells and metastases. These PCs were also expressed in
variable levels in three model ovarian cell lines tested, namely SKOV3, CAOV3 and OVCAR3 cells. Since SKOV3
cells closely represented the PC expression profile of ovarian cancer cells, we chose them to test the effects of PC
silencing using stable gene-silencing shRNA strategy to generate knockdown SKOV3 cells for each expressed PC.
In vitro and in vivo assays confirmed the role of PACE4 in the sustainment of SKOV3 cell proliferation, which was
not observed with the other three PCs. We also tested PACE4 peptide inhibitors on all three cell lines and observed
consequent reduced cell proliferation which was correlated with PACE4 expression. Overall, these data support a
role of PACE4 in promoting cell proliferation in ovarian cancer and provides further evidence for PACE4 as a
potential therapeutic target.
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Ovarian cancer is characterized by a multisequential process, which
involves multiple gains in cell functions, conferring to the transformed
cells the capacity for increased proliferation and metastasis. These
changes are partially mediated by alterations in genetic and protein
expression levels, thus allowing for increased cell division, tissue
invasion, and cell adhesion as well as colonization in new microenvi-
ronments [1]. Among the newest recognized molecular actors involved,
the proprotein convertases (PCs) are important in cancer progression
through their processing and activation of cancer-associated proteins
[2]. Although numerous cancer-associated proteins are likely involved,
proprotein processing can still be considered as a limiting step that
cancer cells require to gain their full self-sustaining capabilities [2].
PCs are a family of serine proteases responsible for protein processing
within the secretory pathway. Nine family members have been identified
inmammalian cells, including furin, PACE4, PC1/3, PC2, PC4, PC5/6,
PC7, PCSK9, and substilisin-kexin isoenzyme 1 (SKI-1) [3]. Only the
first seven PCs cleave their substrates in the C terminus at the R-X-X-R
consensus motif. Among these PCs, furin is ubiquitous, whereas PC1/3
and PC2 are categorized as endocrine specific. Despite the well-accepted
identity of PC substrates, which are largely known from their consensus
cleavage site in their primary sequences, the cleavage specificity among the
enzyme family is still fragmentary and remains difficult to establish
because the PC catalytic domain is highly conserved [4].
The role of PCs has been described in breast cancer [5], head and
neck cancer [6], and recently prostate cancer [7]. Various PC substrates
have recognized roles in cell growth, tumor angiogenesis, invasion, and
metastasis, including secreted growth factors,matrixmetalloproteinases,
and adhesion molecules [8]. The implication of the different PCs in
ovarian cancer is controversial, as PACE4, in contrast to prostate cancer
studies, has been reported to be epigenetically silenced [9] and furin to
be highly expressed in ovarian cancer cells [10]. These data contrast with
those published in open sources such as Oncomine databases
(Compendia Bioscience, Ann Arbor, MI) where PACE4 expression
varies significantly according to data sets but tends to increase in tumor
tissues, just like furin and PC7. Thus, the functional roles and
redundancies of PCs in ovarian cancer context remain unclear.
In the present study, we used molecular silencing [i.e., lentivirus-
delivered small hairpin RNAs (shRNAs)] to knock down each
endogenously coexpressed PC in the SKOV3 cell line and then test
for cell proliferation and tumor progression response. SKOV3 cells are
the most studied models for serous ovarian cancer and display strong
expression of furin, PACE4, PC5/6, and PC7, similar to ovarian cancer
tissues and metastases. Our molecular silencing approach method is
highly specific and permits a better distinction in regards to PC
functional redundancy. We also examined the effects of our recently
developed specific PACE4 inhibitor, namely, the Multi-Leu (ML)
peptide and some peptidomimetic analogs in SKOV3 cells, as well as
two other cell lines, OVCAR3 and CAOV3 cells. The sum of our data
confirms that PACE4, and no other PCs, has an important role in
ovarian cancer cell proliferation and further suggests that PACE4 is a
potential therapeutic target.Materials and Methods
Tissue Sample Collection and Reverse Transcription–Polymerase
Chain Reaction Analysis
Tissues were obtained from Lecce, Italy, with institutional review
board approval by the Human Bioethic Center of University ofSalento and "Vito Fazzi" Hospital, from patients undergoing ovarian
tumor resection. All patients provided written informed consent.
Samples were collected at the time of the surgery, immediately frozen
at −50°C, in isopentane, and stored at −80°C until analysis. Total
cellular RNA was isolated by illustra triplePrep extraction kit (GE
Healthcare) following the manufacturer’s instruction and immediately
used. Total RNA (1μg) was reverse transcribed into cDNAusing theM-
MLV reverse transcriptase enzyme (Invitrogen, Carlsbad, CA).
Polymerase chain reaction (PCR) was carried out using the following
conditions: denaturation at 95°C for 60 seconds, annealing at 60°C for
60 seconds, and extension at 72°C for 60 seconds. PCR products were
visualized after migration on a 1% agarose gel containing 0.25 μg/ml
ethidium bromide and visualized under UV light. Primers used for
reverse transcription–PCR (RT-PCR) are given as follows: Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), forward—5’-
GCATGGCCTTCCGTGTCCC-3’ and reverse—5’-CAATGC-
CAGCCCCAGCGTCA-3 ’ ; PACE4, forward—5 ’ -CTA
TGGATTTGGTTTGGTGGAC-3’ and reverse—5’-AGGCTC-
CATTCTTTCAACTTCC-3’; PC5/6, forward—5’-GATGCAAG-
CAACGAGAACAA-3 ’ and r ev e r s e—5 ’ -GCAGTGGT
CTTTGCTCCTTC-3’; PC7, forward—5’-ATCATTGTCTTCA-
CAGCC-3’ and reverse—5’-AAGCCTGTAGGTCCCTC-3’; and
furin, forward—5’-TATGGCTACGGGCTTTTGG-3’ and reverse—
5’-TTCGCTGGTGTTTTCAATCTCT-3’.
Cell Culture
All cell culture media and FBS were obtained from Wisent
Bioproducts (Saint-Bruno, Québec). SKOV3 and CAOV3 cells were
cultured in Dulbecco's modified Eagle's medium–F12 medium with
10% FBS. OVCAR3 cells were cultivated in RPMI 1640 with 20%
FBS and 10 mg/l insulin (Wisent). HEK293FT cells (Invitrogen)
were grown in Dulbecco's modified Eagle's medium containing 10%
FBS, 6 mM glutamine, and 500 μg/ml G418. All cell lines were
cultured at 37°C in a water-saturated atmosphere with 5% CO2.
Lentiviral Particle Production and shRNA Transduction
MISSION RNAi pLKO.1-puro vectors for each PC were purchased
from Sigma-Aldrich (St Louis, MO) as described in [11,12]. Lentivirus
particles containing these shRNAs were produced in theHEK293FT cell
line. shRNA sequences are listed as follows with their Sigma The RNAi
Consortium (TRC) number: furin—CCTGTCCCTCTAAAGCAA-
TAA (TRC: TRCN0000075238), PACE4—CCTGGAAGATTAC-
TACCATTT (TRC: TRCN0000075250 ) , PC5 /6—
TTTCGGAAATTCATTGGTTGGT (TRC: TRCN0000051179),
and PC7—GCACTATCAGATCAATGACAT (TRCN0000072394).
SKOV3 cells were infected with the virus-containing media and selected
with 3 μg/ml puromycin (the lowest concentration able to eliminate
untransfected cells) 2 days after infection. Knockdown cell lines were
further cultured under selection conditions. shRNA sequences were
selected on the basis of results shown by Couture et al. [11].Reverse Transcription– andReal-TimePolymeraseChainReaction
Total RNA was extracted from cell pellet obtained following
trypsin treatment using the Qiagen RNA isolation kit (Qiagen,
Valencia, CA), and quality was assessed using RNA Nano Chips
using an Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA).
Relative expression levels were calculated using β-actin as a reference
gene like in [11]. Experiments were performed at least three times in
duplicate (n = 3). Primers used are those defined in [11].
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The XTT Cell Proliferation Kit II (Roche Applied Science,
Indianapolis, IN) was used following the manufacturer’s instructions.
This assay is a nonwash colorimetric assay for cell proliferation and cell
viability measurement. For this assay, an 2,3-Bis(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) tetrazolium salt is
reduced by dehydrogenase enzymes in metabolically active cells in a
soluble formazan, allowing direct measure of metabolic activity without
removing the media from the plate. Briefly, 1000 cells of each cell line
were plated onto 96-well plates in 100 μl of complete culture media.
Every following 24 hours until 96 hours of growth, XTT reagent was
added to each well, and the plates were incubated for 5 hours.
Absorbance values weremeasured at 490 nmwith a reference at 690 nm
in amicroplate reader (SpectraMax 190;Molecular Devices, Sunnyvale,
CA). Experiments were performed in five replicates for each cell line at
least five times (n = 5).Means were reported for the 24-hour absorbance
value for each cell line.
Clonogenicity Assays
A clonogenicity assay was performed by plating 400 cells of each cell
line in six-well plates with 2 ml of complete media for 15 days. Media
were then discarded, and 1 ml of 5 mg/ml methylene blue with 50%
methanol was added. After 10 minutes, wells were rinsed carefully with
distilled water and dried to allow for the manual counting of stained
colonies. Only colonies with N40 cells were considered.
Human Tumor Xenograft Models
Exponentially growing cells (2 × 106) were collected and injected
subcutaneously in shoulders and flanks of five to six female Nu/Nu
mice (Charles River, Saint-Bruno, Québec) for each cell line. Tumor
volumes were determined using a digital caliper three times per week
using the following formula: tumor volume = (L × W2) × π/6, where
L is the tumor length and W is the tumor width. At the end of the
experiment, tumors were excised and fixed in formalin before paraffin
embedding for further immunohistochemistry (IHC).Figure 1. PC expression profile among ovarian cancer tissues and
cell lines. (A) RT-PCR evaluation of the PCs furin, PACE4, PC5/6,
and PC7 in normal ovaries (n = 4), ovarian primary tumors (n = 4),
ascitic cells (n = 2), and metastases (n = 2) is shown. (B) RT-qPCR
analyses of relative mRNA levels for each PC member in the
SKOV3, CAOV3, and OVCAR3 cells (n = 3) are shown. Data are
means ± SEM of experiments performed in duplicate.IHC of Tissue Markers in Xenograft Model Tumors
IHC were performed on 5-μm tumor sections in the Department of
Pathology of the Centre Hospitalier Universitaire de Sherbrooke,
Québec (CHUS) (Sherbrooke) using a standard streptavidin-biotin-
peroxidase immunostaining procedure with a Ventana NexES auto-
stainer and the solvent-resistant DAB Map detection kit (Ventana
Medical Systems, Tucson, AZ) using ready-to-use solutions (Ki67 and
E-cadherin) purchased from Dako, Burlington, Ontario, Canada.
Ki67-positive cells were manually counted in up to five × 400 light
microscope representative fields per tumor (containing an average of
150 cells). Total counts were reported as total cell number per field.
E-cadherin protein levels were quantified using the yellow channel of
a cyan, magenta, yellow, key (CMYK) color model with pictures
taken with a Super Coolscan 9000 scanner (Nikon, Tokyo, Japan)
using Fiji software (Open Source) [13], and quantification was
performed using Image-Pro software (Media Cybernetics, Bethesda,
MD). To avoid quantification of any nontumoral area (e.g., skin and
fat), the xenograft sections were counterstained using hematoxylin
and eosin in addition to staining the estrogen receptor, a
positive marker of SKOV3 cells. Pictures with × 100 and ×
400 magnifications were acquired using an Axioskop 2 phase-
contrast microscope (Carl Zeiss, Thornwood, NY) and processed
using Image-Pro software.Peptide and Peptidomimetic Inhibitors
All compounds used in this study were prepared as previously
described [14].
Growth Inhibition Assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell
proliferation assays were performed as described previously [15].
Briefly, cells were plated onto 96-well poly-(L)-lysine–coated plates at
a density of either 1500 SKOV3 or 4500 OVCAR3 or 3000 CAOV3
cells per well. After 24 hours of incubation, the media were changed,
and peptides were added to fresh complete media. The metabolic
activity was monitored as described previously by Levesque et al. [15].
Statistical Analysis
All experiments were repeated at least five times, and the results were
expressed as means ± SEM. Statistical analysis was done using Student’s
t test to calculate P values and determine statistical significance.
Results
PCExpression Pattern inOvarianCancer Stages andCellModels
On the basis of the data available in Oncomine databases, PCs
trend toward a global overexpression in ovarian cancer when
compared to normal tissues. We first decided to investigate this
trend in PC expression using RT-PCR in tissue samples originating
from normal ovaries, ovarian tumors, ascitic cells, and distant
metastases. As shown in Figure 1A, furin, PACE4, PC5/6, and PC7
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and metastases), confirming the Oncomine databases.
The expression of endogenous PCs was further examined in well-
known ovarian cancer cell models, including SKOV3, OVCAR3, and
CAOV3. Reverse transcription– and real-time PCR (RT-qPCR)
analyses were performed for each PC, and the expression was
normalized using β-actin mRNA levels. Results are presented in
Figure 1B. Furin is expressed in all analyzed cell lines, as expected.
SKOV3 cells also expressed high levels of PACE4, PC5/6, and PC7,
when compared to other cell lines. In addition to furin, OVCAR3
cells expressed only PC5/6 and PC7, whereas CAOV3 expressed only
PACE4 and PC5/6.
Down-Regulation of Endogenously Expressed PCs
Because the overall expression of furin, PACE4, PC5/6, and PC7 is
increased in ovarian cancer tissues compared to normal tissues from
Oncomine databases and our analysis further validated this result
(Figure 1A), we chose SKOV3 cell line as the best model to examine
the role of each PC in cell proliferation and tumor progression,
because this cell line coexpresses high levels of these PCs. A lentiviral
delivery strategy was used to generate stable shRNA-expressing cells
for each of these PCs [11,12]. Consistent with the previously
determined gene silencing efficiency for human PC shRNA sets [11],
the two most efficient sequences were used to knock down these PCsFigure 2. PC expression profile in SKOV3 cells. Knockdown levels for fu
following the generation of two stable knockdown cell lines per PC. Dat
performed in duplicate. *P b .05 and **P b .01.in SKOV3 cells, and the most efficiently silenced cell line was further
used for the cell-based assays. Knockdown efficiency was assessed by
RT-qPCR using the nontarget (NT) shRNA-expressing cells as a
control. The results are presented in Figure 2. The residual expression
in the selected knockdown cells was 16% for shfurin, 28% for
shPACE4, 4% for shPC5/6, and 37% for shPC7.
PC7 and PACE4 Knockdowns Reduce the Cell Proliferation
and Colony Formation of SKOV3 Cells
XTT cell proliferation assays were used to determine the
importance of each PC in cell growth [12,16]. Cell growth was
monitored for 96 hours and plotted using the respective increase of
absorbance relative to each starting value at 24 hours. The results are
presented in Figure 3A. PACE4 and PC7 knockdown cells exhibited a
significantly reduced growth rate compared to the NT control cell
line. The knockdown cell lines displayed an overall reduction of 35%
for shPC7 and 34% for shPACE4 relative to the control cells.
Interestingly, the growth rate of furin knockdown cells remained
unchanged compared to the control cells, whereas PC5/6 knockdown
only slightly affected cell growth (20% reduction of proliferation
compared to NT).
Cell clonogenicity potential, which is defined as the capacity of a
single cell to form a colony, was further assessed because it involves
cell growth factor self-sufficiency, an important facet of cancer cellrin (A), PACE4 (B), PC5/6 (C) and PC7 (D) were assessed by RT-qPCR
a aremeans±SEMof at least three independent experiments (n=3)
Figure 3. In vitro cell growth assay. (A) XTT assays were performed for each selected PC knockdown cell line. Colorimetric measures
(OD490–OD690 nm) were taken at 24, 48, 72, and 96 hours after seeding 1× 10
3 cells per well. Growth wasmonitored as percentage of the
24-hour value. Data are means ± SEM of at least three independent experiments (n = 3) performed in duplicate. *P b .05. (B) Colony
formation assay was performed on seeding 200 cells in six-well plates, which were allowed to grow 15 days before being stained and
manually counted. Representative colonies are shown. Data are means ± SEM of at least three independent experiments (n = 3)
performed in duplicate. *P b .05 and **P b .01.
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plates) and allowed 10 days to form colonies, which were stained and
manually counted. The results are presented in Figure 3B. Consistent
with the proliferation assays, PACE4 and PC7 knockdown cells
formed significantly fewer colonies than the NT control cells
(42% and 40%, respectively), and no significant changes were
observed for the furin and PC5/6 knockdown cells.
PACE4 Gene Silencing Prevents the Xenograft Progression in
Athymic Nude Mice
As the cell culture environment has the obvious limitations of in
vitro experiments, the physiological context was then considered in
an effort to validate the obtained cell proliferation and clonogenicity
results. Each knockdown cell line was subcutaneously xenografted on
athymic nude mice, and tumor volumes were monitored over time.
Mean tumor volumes were determined and plotted (Figure 4, A and
B). As previously reported, a tumor latency phase was observed
before the tumors reached an exponential growth phase [17].
Interestingly, in contrast with the results from the in vitro assays,
only the PACE4 knockdown cell–derived xenografts had a
statistically significant lower growth rate when compared to control
NT cells (37% overall reduction of tumor sizes). Moreover, the PC7
knockdown xenograft behavior was strikingly different when
compared to the in vitro assay as their tumor growth rates were
significantly higher than the growth rates of the control tumors (29%
overall increase in tumor sizes). Consistent with the in vitro assays,
the growth rates of both furin and PC5/6 knockdown tumors
remained unchanged.
At the end of the experiment, the mice were killed, and tumors
were excised and weighed. The average tumor weights are
reported in Figure 4C. Consistent with their growth rates, PC7
knockdown–derived tumors had significantly higher weights (250
± 30 mg) than the PACE4 knockdown–derived tumors, which
were significantly lower (100 ± 20 mg) when compared to the
control tumors (170 ± 20 mg). No significant changes in tumor
weights were observed for the furin and PC5/6 knockdowns
(averages of 170 and 150 mg, respectively).Molecular Markers Suggest that the Proliferation Index Is
Decreased in PACE4 Knockdown Cell–Derived Xenografts and
that PC7 Acts as a Tumor Growth Restrictor In Vivo
Molecular markers were analyzed by IHC in xenografts to evaluate
the biologic processes of proliferation that might clarify the growth
disparity between in vitro and in vivo conditions. Analyses were
performed on excised xenograft sections with the Ki67 proliferation
marker, which stains nuclei and allows the proliferating cells to be
discriminated. Thus, the determination of Ki67-positive nuclei
provided insights supporting tumor growth behavior. The results
presented in Figure 5A indicated that cell proliferation indexes among
the PC knockdown cell–derived xenografts were equal compared to
the NT controls with the exception of PACE4 knockdown cell–
derived xenografts, which had a significantly lower index (70%), and
furin knockdown cell–derived xenografts, where only a slight but
statistically significant difference was observed (87%). These
observations supported the growth phenotype observed for PACE4-
silenced cells and tumors.
E-cadherin has a dual role in the different phases of ovarian cancer
metastasis [18]. E-cadherin has antiproliferative effects on cells before
they undergo epithelial-to-mesenchymal transition in many types of
cancers, including epithelial ovarian cancers (EOCs) [19]. IHC were
performed against E-cadherin on the xenograft sections, and relative
protein levels were quantified (Figure 5, B and C). Interestingly,
significantly higher E-cadherin levels were observed in the PC7-
silenced xenografts (176%) without significant variation for the other
xenograft types assayed when compared to controls.
PACE4 Inhibitors Display PACE4-DependentGrowth Inhibition
Properties when Applied on Ovarian Cancer Cell Models
To further test the effect of PACE4 inhibition, we examined the
pharmacological effect of the previously described PACE4 inhibitor
ML peptide and its peptidomimetic analogs on the proliferation of
the three model cell lines. This analysis takes into account the variable
levels of PACE4 expression. The PACE4 inhibitor Ac-LLLLRVKR-
NH2 [15] and its analog Ac-[DLeu]LLLRVKR-NH2 [14] have
inhibitory constants (Ki) in the low nanomolar range against PACE4
Figure 4. In vivo xenograft formation assay. (A) Exponentially
growing cells (2 × 106) were injected subcutaneously in athymic
nudemice (four sites per mouse; five to six mice per group). Tumor
volumes were monitored regularly. Data are means ± SEM of all
tumor volumes per group. *P b .05 and **P b .01. (B) Pictures of
representative xenografted mice show tumor size differences.
(C) On day 50, tumors were excised after mice killing, and tumor
weights were measured. Data are means ± SEM of all tumor
weights per group. *P b .05.
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[DLeu]LLLRVKR-NH2 displayed half-maximal growth inhibition
concentration (IC50) in the mid-micromolar range in the PACE4-
positive SKOV3 (320 and 220 μM, respectively) and CAOV3 (450and 220 μM, respectively; Figure 6). A more potent analog, which
has the 4-amidinobenzylamide (Amba), an arginine mimetic, at its C
terminus; Ac-LLLLRVK-Amba is almost 10-fold more potent for
PACE4 (Ki = 3 nM) [14]) and had lower IC50s (140 and 70,
respectively) for the SKOV3 and CAOV3 cells). When applied on the
PACE4-negative OVCAR3 cells, the peptide displayed no significant
growth inhibition with concentrations up to 500 μM (concentration
limit due to solubility properties). Additionally, a negative control
peptide lacking the critical R residue at the C terminus, Ac-
LLLLRVKA-NH2, did not exhibit antiproliferative properties in
PACE4-expressing cell lines. These data support PACE4 dependence
in ovarian cancer for sustained proliferation.
Discussion
According to American and European statistics, ovarian cancer is the
most lethal of all gynecological cancers. The latest projection for 2013
in the United States reports that approximately 22,240 women
received a new diagnosis of ovarian cancer, leading to 14,030 deaths
[20]. In Europe, more than 65,500 new cases were estimated in 2012,
leading to 42,700 deaths [21]. This affliction is commonly called the
“silent killer” because its evolution does not indicate any clear
symptoms [22].
PCs are essential for physiological and pathologic cellular processes.
These important enzymes have critical roles in neoplasm formation,
progression, and metastasis through the processing of a variety of
oncoproteins, such as growth factors and their receptors, as well as
membrane and extracellular matrix proproteins involved in tumor
progression [23,3]. The prediction of their substrate cleavage
specificities is hindered due to the highly conserved nature of their
catalytic sites and observed redundancies using in vitro assays.
Nonetheless, the ability to discriminate the distinct and redundant
functions that drive cancer-related aspects of a given cancer type
remains possible within an in vivo context, because PCs have different
tissue and intracellular localizations. Because we believe that targeting
PCs upstream of converging cancer pathways could attenuate the
aggressiveness of cancer cells with limited physiological drawbacks on
normal cells [3], this is of great relevance for the development of
targeted therapeutic strategies. The question remains as to which PCs
need to be targeted, to provide the best chances of a beneficial effect.
To evaluate the relative cancer-sustaining functions of each PC in
ovarian cancer, we used a gene-silencing method to generate
individual cell lines, each lacking an endogenously expressed PC
member. Because pharmacological compounds selectively targeting
each member of the PC family are limited, this method represents the
best option allowing for the direct comparison of the implication of
PCs in cell proliferation both in vitro and in vivo [12]. On the basis of
the observation that ovarian tumor tissues, and also ascites cells and
metastases, display variable levels of PC expression (Oncomine
databases; Figure 1A), we opted for the SKOV3 cells to explore the
relative implication of each PCs, as they coexpressed the four relevant
PCs: furin, PACE4, PC5/6, and PC7 (see Figure 1B).
Using in vitro proliferation assays, we observed the effects of
PACE4 and PC7 molecular silencing through proliferation and
colony formation assays in these cells. In vivo xenograft formation
assays supported the phenotype observed with PACE4-silenced cells;
however, the observations in this assay contrasted with PC7
knockdown cells, which displayed unexpected increased tumor
progression capabilities when implanted in athymic nude mice,
contrasting with the in vitro proliferation assays. Although we found a
Figure 5. Xenograft IHC analyses. IHC were performed on 0.5-μm tissue sections of excised xenografts. (A) Ki67 and (B) E-cadherin
immunostaining quantification using CMYK quantification in tumor areas were confirmed by hematoxylin and eosin standard
counterstainings. (C) Representative fields are shown at × 400 magnification, and scale bars represent 25 μm. *P b .05 and ***P b .001.
416 PCs in Ovarian Cancer Longuespée et al. Translational Oncology Vol. 7, No. 3, 2014decreased growth rate for the shPACE4 tumors, we observed a greatly
increased proliferation of shPC7 tumors. Such contradictory results
between in vitro and in vivo growth conditions have been reported by
Couture et al. for prostate cancer cell lines [11], and these results
highlight the importance of also validating in vitro observations in a
more physiological context to take account of the conditions within
the tumor microenvironment.
We also examined various biomarkers in relation to PACE4 and
PC7 knockdown cell–derived xenografts. A statistically significant
reduction in the Ki67 proliferation index was observed in the PACE4-
silenced xenograft, supporting the observed growth phenotype. This
phenomenon was in agreement with our previous report resulting in
similar conclusions [11].
Evaluation of E-cadherin levels, an epithelial protein at the surface
of the cells, provides a partial explanation of the surprising in vivo
growth properties of shPC7 SKOV3 xenografts. The molecular
context differentiating in vitro and in vivo assays consists not only in
the growth factor availability in the animal model environment but
also in the multiple cell interactions that exist in the pseudotumor
that forms the xenograft. These intercellular interactions may be
associated to the dramatic overgrowth of shPC7 xenografts, comparedto growth of the individual cell line in vitro. Intercellular interactions
are partially mediated by E-cadherin that allows a Ca2+-dependent
homophylic interaction. E-cadherin has a dual role in the different
phases of ovarian cancer metastasis [18]. It was recently shown that E-
cadherin was able to promote SKOV-3 cell line overgrowth, in vitro
[24]. In prostate cancer, E-cadherin has been proposed as a marker for
tumor aggressiveness because it is re-expressed at a late stage of
metastatic progression [25]. The differential in vivo growth of E-
cadherin-positive and E-cadherin-negative DU145 prostatic cell
sublines was recently evaluated. The result of this study indicated
that an E-cadherin-positive xenografted cell line grows more rapidly
than an E-cadherin-negative cell line [26]. In a brain tumor
model, the overexpression of E-cadherin has been associated
with an aggressive phenotype [27]. IHC analyses indicated increased
E-cadherin levels in SKOV3 shPC7 tumors, which could partially
explain the in vivo significantly higher growth rate of shPC7 tumors
when considering the role of E-cadherin. However, the number of
Ki67-positive cells remained unchanged in the shPC7 tumors
compared to the control tumors. E-cadherin has been shown not to
have any correlation with Ki67 for lesion classification in uterine
cervical cancer [28].
Figure 6. Antiproliferative activity of PACE4 inhibitors using ovarian
cancer cells. (A) Dose-response growth inhibition curves of the ML
peptide and its peptidomimetic analogs on SKOV3 cells are shown.
(B) IC50 of the four peptides on the PACE4-positive SKOV3 and
CAOV3 cells and the PACE4-negative OVCAR3 cells is shown.
Dose-response curves are representative experiments, and data in
the table are means ± SEM of at least four independent
experiments performed in triplicate. NC indicates that the curve
did not converge at concentration below 500 μM.
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numerous neoplasias, such as oral tongue carcinoma [29], hepato-
cellular carcinoma [30], glioma [31], skin cancer [32,33], and
prostate cancer [7]. Whereas these studies mostly examined
overexpression of PACE4, our present study focused on gene
silencing as a predictive approach to define potential therapeutic
benefits, as we have also recently demonstrated with prostate cancer
[7,11,15]. The role of PACE4 in ovarian homeostasis has already
been documented [34], and its expression has also been shown to be
decreased in ovarian cancer tissues [9]. However, this latter study is in
contradiction with gene expression databases such as Oncomine. This
may be due to results that suggest that expression is also linked to
various tumor grades [10].
As our gene silencing studies indicate that the inhibition of PACE4
might be beneficial in ovarian cancer, we then tested the application
of pharmacological inhibitors of PACE4. In a recent work, we
developed a peptide-based inhibitor targeting PACE4, named the ML
peptide inhibitor. Using ML peptide inhibitors, we provided evidence
of their effectiveness on prostate cancer cell lines [15]. These peptides
were designed on the basis of the observation that PC7 prodomain-
based peptides with nonpolar amino acid residues at P6 and P7
positions have better inhibition potency toward PACE4 than furin
[35]. The N-terminal addition of four Leu residues to the consensus
PC motif created the ML peptide (Ac-LLLLRVKR-NH2). This
addition allowed low nanomolar Ki to be reached (Ki = 20 nM) and
provided a higher selectivity for PACE4 than for furin by up to 20- to
22-fold [15]. Our studies have shown that, on prostate cancer cell
lines, such as DU145 and LNCaP, ML-peptide displays a
pharmacological effect with an IC50 in the micromolar range. In
the present study, we used the PACE4-positive SKOV3 and CAOV3cells together with the OVCAR3 cells to compare PACE4-dependent
effect on cell proliferation. Again, the Ac-LLLLRVKR-NH2 and its
analog Ac-[DLeu]LLLRVKR-NH2 had IC50s in the micromolar
range for the PACE4-positive cells but did not display any inhibitory
effect on the PACE4-negative OVCAR3 cell proliferation (Figure 6).
When using the Ac-LLLLRVK-Amba peptidomimetic analogs,
which display much lower Ki values (i.e., 3 nM) toward PACE4
and a higher stability profile in vitro, the IC50 values lowered
considerably, thus supporting a PACE4-linked effect [14]. This
PACE4 dependance is also supported by a negative control peptide
(Ac-LLLLRVKA-NH2), which had no effects on proliferation of any
of the tested cell lines, corroborating the notion of a PC-dependent
growth inhibition as the peptide does not possess inhibitory activity
toward PACE4. These key results demonstrate that pharmacological
inhibition of PACE4 phenocopies the gene silencing approach and
suggests new strategies for targeted therapy of ovarian cancer. This
highlights the possibility of using PC-based approach to treat
ovarian cancer.
The present study, along with our previous work on prostate
cancer, increasingly suggests that PCs can be attractive targets for the
development of novel therapies for various neoplasias. Our results
offer important insights into the implication of PCs in carcinogenesis
and progression of ovarian cancer. Although our results raise the hope
for a major role of PACE4 in various cancer types, we cannot assume
that this will be generalized to most tumor types. However, further
studies with additional cancer types are now justified. Moreover, this
study highlights the fact that, in opposition to prostate cancer where
only PACE4 is overexpressed among the PCs, all PCs analyzed are
overexpressed in ovarian cancer despite the proliferative functions
being limited to PACE4. This indicates that the simple observation of
overexpressed proteases, such as PCs, does not necessarily imply that
it can be a pharmacological target. Validation steps that focus on
inhibition rather than overexpression are clearly required.
Further studies in the fields of EOCs would also be interesting,
starting with the use of other cell lines that would represent each
different type of EOC. Recent studies suggest that EOC may actually
initiate from a primary metastasis of müllerian tissues to develop in
the ovarian environment [36,37]. Depending of the origin of the
initiating cell, different affliction types may occur. Serous cancers may
initiate from a tubal origin and endometrioid cancers from an
endometrial origin. These two types of cancers represent the most
prevalent ones and bear very different morphologic properties. It
would be very relevant to discriminate whether PC implications are
constant between these two types of EOC.
Finally, the determination of PACE4-specific substrates in ovarian
cancer progression would pave the way to a better understanding of
molecular and cellular pathways in tumorigenesis but also potentially
reveal biomarkers regulated by this enzyme. Nowadays, N-
terminomics methods based on mass spectrometry allow one to
decipher the action of an enzyme by the characterization of its
generated N-terminal fragments [38]. Evaluation of the general action
of an enzyme is the crucial step to describe biologic mechanistics, and
it may be of great relevance to reveal the key position of PACE4
among molecular events of ovarian cancer progression. Other mass
spectrometry–based approaches for the analysis of tissues regarding
the anatomic context [39–42] may also be useful for the exploration
of molecular events occurring in xenografts. Indeed, it would be
interesting to compare the molecular events occurring between the
developed tissue and the surrounding environment or within the
418 PCs in Ovarian Cancer Longuespée et al. Translational Oncology Vol. 7, No. 3, 2014tissue itself between the different interacting cell types, for example,
between blood vessels and the cancerous cells.
In conclusion, the present study provides a new outlook for the use
of PACE4 inhibitors in neoplastic afflictions.
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